BaseMap ABE Launched for Off-Target Characterization in Base Editing Therapeutic Development

Cambridge, U.K.-based Broken String Biosciences launched BaseMap ABE, built on the company’s INDUCE-seq^® technology, to support adenine base editing (ABE) applications.

Base editing is gaining momentum as a powerful therapeutic tool that enables precise single-base genomic changes. However, as therapeutic programs increasingly adopt ABE, researchers require reproducible and standardized methods to comprehensively characterize unintended off-target editing events, according to Terry Pizzie, CEO, Broken String Biosciences.

Unlike prediction-based approaches, BaseMap ABE generates genome-wide data directly from biologically relevant cells, providing researchers with clear understanding of editor specificity under physiologically relevant conditions, he says, adding that the platform enables rapid, unbiased identification of off-target events, while generating standardized and robust data to support guide optimization, editor selection and preclinical decision making.

BaseMap ABE represents the first phase of Broken String Biosciences’ expansion into base editing applications. Through the Early Access Program, the company states that it will collaborate closely with researchers developing genome editing therapies, providing experience for early adopters and generating feedback to inform future product development.

The post BaseMap ABE Launched for Off-Target Characterization in Base Editing Therapeutic Development appeared first on GEN - Genetic Engineering and Biotechnology News.